A Full-Service Contract Development and Manufacturing Organization (CDMO) is a company that provides comprehensive services across the entire drug development and manufacturing lifecycle, from early-stage development to commercial-scale production. These organizations offer a wide range of services to pharmaceutical and biotechnology companies, allowing them to outsource various aspects of drug development and manufacturing to external partners with specialized expertise and capabilities.
The global Full-Service CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Full-Service CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Full-Service CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Full-Service CDMO in Pharmaceutical Company is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Full-Service CDMO include Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Full-Service CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Full-Service CDMO.
The Full-Service CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Full-Service CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Full-Service CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Full-Service CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Full-Service CDMO 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 API CDMO
1.2.3 FDF CDMO
1.2.4 Packaging CDMO
1.2.5 Clinical CDMO
1.3 麻豆原创 by Application
1.3.1 Global Full-Service CDMO 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Full-Service CDMO 麻豆原创 Perspective (2019-2030)
2.2 Global Full-Service CDMO Growth Trends by Region
2.2.1 Global Full-Service CDMO 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Full-Service CDMO Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Full-Service CDMO Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Full-Service CDMO 麻豆原创 Dynamics
2.3.1 Full-Service CDMO Industry Trends
2.3.2 Full-Service CDMO 麻豆原创 Drivers
2.3.3 Full-Service CDMO 麻豆原创 Challenges
2.3.4 Full-Service CDMO 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Full-Service CDMO Players by Revenue
3.1.1 Global Top Full-Service CDMO Players by Revenue (2019-2024)
3.1.2 Global Full-Service CDMO Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Full-Service CDMO 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Full-Service CDMO Revenue
3.4 Global Full-Service CDMO 麻豆原创 Concentration Ratio
3.4.1 Global Full-Service CDMO 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Full-Service CDMO Revenue in 2023
3.5 Global Key Players of Full-Service CDMO Head office and Area Served
3.6 Global Key Players of Full-Service CDMO, Product and Application
3.7 Global Key Players of Full-Service CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Full-Service CDMO Breakdown Data by Type
4.1 Global Full-Service CDMO Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Full-Service CDMO Forecasted 麻豆原创 Size by Type (2025-2030)
5 Full-Service CDMO Breakdown Data by Application
5.1 Global Full-Service CDMO Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Full-Service CDMO Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Full-Service CDMO 麻豆原创 Size (2019-2030)
6.2 North America Full-Service CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Full-Service CDMO 麻豆原创 Size by Country (2019-2024)
6.4 North America Full-Service CDMO 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Full-Service CDMO 麻豆原创 Size (2019-2030)
7.2 Europe Full-Service CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Full-Service CDMO 麻豆原创 Size by Country (2019-2024)
7.4 Europe Full-Service CDMO 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Full-Service CDMO 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Full-Service CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Full-Service CDMO 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Full-Service CDMO 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Full-Service CDMO 麻豆原创 Size (2019-2030)
9.2 Latin America Full-Service CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Full-Service CDMO 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Full-Service CDMO 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Full-Service CDMO 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Full-Service CDMO 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Full-Service CDMO 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Full-Service CDMO 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Full-Service CDMO Introduction
11.1.4 Lonza Revenue in Full-Service CDMO Business (2019-2024)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Full-Service CDMO Introduction
11.2.4 Catalent Revenue in Full-Service CDMO Business (2019-2024)
11.2.5 Catalent Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Full-Service CDMO Introduction
11.3.4 Thermo Fisher Scientific Revenue in Full-Service CDMO Business (2019-2024)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Details
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Full-Service CDMO Introduction
11.4.4 Samsung Biologics Revenue in Full-Service CDMO Business (2019-2024)
11.4.5 Samsung Biologics Recent Development
11.5 Fareva
11.5.1 Fareva Company Details
11.5.2 Fareva Business Overview
11.5.3 Fareva Full-Service CDMO Introduction
11.5.4 Fareva Revenue in Full-Service CDMO Business (2019-2024)
11.5.5 Fareva Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Details
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Full-Service CDMO Introduction
11.6.4 WuXi AppTech Revenue in Full-Service CDMO Business (2019-2024)
11.6.5 WuXi AppTech Recent Development
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Details
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Full-Service CDMO Introduction
11.7.4 WuXi Biologics Revenue in Full-Service CDMO Business (2019-2024)
11.7.5 WuXi Biologics Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Details
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Full-Service CDMO Introduction
11.8.4 Siegfried Revenue in Full-Service CDMO Business (2019-2024)
11.8.5 Siegfried Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Details
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Full-Service CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Full-Service CDMO Business (2019-2024)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Details
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Full-Service CDMO Introduction
11.10.4 Asymchem Revenue in Full-Service CDMO Business (2019-2024)
11.10.5 Asymchem Recent Development
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Details
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Full-Service CDMO Introduction
11.11.4 Pfizer CentreOne Revenue in Full-Service CDMO Business (2019-2024)
11.11.5 Pfizer CentreOne Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Details
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Full-Service CDMO Introduction
11.12.4 Delpharm Revenue in Full-Service CDMO Business (2019-2024)
11.12.5 Delpharm Recent Development
11.13 Recipharm
11.13.1 Recipharm Company Details
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Full-Service CDMO Introduction
11.13.4 Recipharm Revenue in Full-Service CDMO Business (2019-2024)
11.13.5 Recipharm Recent Development
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Details
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Full-Service CDMO Introduction
11.14.4 AGC Pharma Chemicals Revenue in Full-Service CDMO Business (2019-2024)
11.14.5 AGC Pharma Chemicals Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Details
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Full-Service CDMO Introduction
11.15.4 Boehringer Ingelheim Revenue in Full-Service CDMO Business (2019-2024)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Vetter
11.16.1 Vetter Company Details
11.16.2 Vetter Business Overview
11.16.3 Vetter Full-Service CDMO Introduction
11.16.4 Vetter Revenue in Full-Service CDMO Business (2019-2024)
11.16.5 Vetter Recent Development
11.17 Curia
11.17.1 Curia Company Details
11.17.2 Curia Business Overview
11.17.3 Curia Full-Service CDMO Introduction
11.17.4 Curia Revenue in Full-Service CDMO Business (2019-2024)
11.17.5 Curia Recent Development
11.18 Aenova
11.18.1 Aenova Company Details
11.18.2 Aenova Business Overview
11.18.3 Aenova Full-Service CDMO Introduction
11.18.4 Aenova Revenue in Full-Service CDMO Business (2019-2024)
11.18.5 Aenova Recent Development
11.19 Porton
11.19.1 Porton Company Details
11.19.2 Porton Business Overview
11.19.3 Porton Full-Service CDMO Introduction
11.19.4 Porton Revenue in Full-Service CDMO Business (2019-2024)
11.19.5 Porton Recent Development
11.20 Piramal
11.20.1 Piramal Company Details
11.20.2 Piramal Business Overview
11.20.3 Piramal Full-Service CDMO Introduction
11.20.4 Piramal Revenue in Full-Service CDMO Business (2019-2024)
11.20.5 Piramal Recent Development
11.21 Strides Pharma
11.21.1 Strides Pharma Company Details
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Full-Service CDMO Introduction
11.21.4 Strides Pharma Revenue in Full-Service CDMO Business (2019-2024)
11.21.5 Strides Pharma Recent Development
11.22 NextPharma
11.22.1 NextPharma Company Details
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Full-Service CDMO Introduction
11.22.4 NextPharma Revenue in Full-Service CDMO Business (2019-2024)
11.22.5 NextPharma Recent Development
11.23 Famar
11.23.1 Famar Company Details
11.23.2 Famar Business Overview
11.23.3 Famar Full-Service CDMO Introduction
11.23.4 Famar Revenue in Full-Service CDMO Business (2019-2024)
11.23.5 Famar Recent Development
11.24 Jubilant
11.24.1 Jubilant Company Details
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Full-Service CDMO Introduction
11.24.4 Jubilant Revenue in Full-Service CDMO Business (2019-2024)
11.24.5 Jubilant Recent Development
11.25 Alcami
11.25.1 Alcami Company Details
11.25.2 Alcami Business Overview
11.25.3 Alcami Full-Service CDMO Introduction
11.25.4 Alcami Revenue in Full-Service CDMO Business (2019-2024)
11.25.5 Alcami Recent Development
11.26 Euroapi
11.26.1 Euroapi Company Details
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Full-Service CDMO Introduction
11.26.4 Euroapi Revenue in Full-Service CDMO Business (2019-2024)
11.26.5 Euroapi Recent Development
11.27 Eurofins
11.27.1 Eurofins Company Details
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Full-Service CDMO Introduction
11.27.4 Eurofins Revenue in Full-Service CDMO Business (2019-2024)
11.27.5 Eurofins Recent Development
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Details
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Full-Service CDMO Introduction
11.28.4 Avid Bioservices Revenue in Full-Service CDMO Business (2019-2024)
11.28.5 Avid Bioservices Recent Development
11.29 BioVectra
11.29.1 BioVectra Company Details
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Full-Service CDMO Introduction
11.29.4 BioVectra Revenue in Full-Service CDMO Business (2019-2024)
11.29.5 BioVectra Recent Development
11.30 CPL
11.30.1 CPL Company Details
11.30.2 CPL Business Overview
11.30.3 CPL Full-Service CDMO Introduction
11.30.4 CPL Revenue in Full-Service CDMO Business (2019-2024)
11.30.5 CPL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
听
听
*If Applicable.
